Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 4/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.43 |
| ▸ | DHFR | P00374 | 4/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 2/20 | 0.39 |
| ▸ | RXRB | P28702 | 2/20 | 0.39 |
| ▸ | RXRG | P48443 | 2/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.37 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5582222 | 0.89 | KDM4E (0.40) | ADORA1FFAR1LTB4RRXRARXRB | |
| SCHEMBL5581661 | 0.87 | ADORA1 (0.44) | ADORA1FFAR1LTB4RRXRARXRB | |
| SCHEMBL5581762 | 0.81 | ADORA1 (0.43) | ADORA1ADORA2ADHFRLTB4RCSNK2A2 | |
| SCHEMBL5581757 | 0.81 | ADORA1 (0.43) | ADORA1ADORA2ADHFRLTB4RCSNK2A2 | |
| SCHEMBL5582238 | 0.80 | MAP4K4 (0.52) | ADORA1ADORA2ADHFRCSNK2A2CSNK2B | |
| SCHEMBL5582167 | 0.79 | KDM4E (0.41) | ADORA1FFAR1LTB4R | |
| SCHEMBL5581989 | 0.79 | DHFR (0.51) | ADORA1ADORA2ADHFRMAP4K4FYN | |
| SCHEMBL5582142 | 0.76 | CCNC (0.42) | ADORA1ADORA2ADHFRFYN | |
| SCHEMBL5581566 | 0.76 | ADORA1 (0.41) | ADORA1LTB4RCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL5582145 | 0.76 | CCNC (0.42) | ADORA1ADORA2ADHFRFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | KYOWA HAKKO KOGYO CO.,LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| EP-1726584-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | AGTR2, ABL1, AGTR1 | ADORA1 406/4885ADORA2A 1251/4885DHFR 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.